Moxifloxacin Krka (Moxifloxacin)

Moxifloxacin Krka is a fluoroquinolone used for infections caused by susceptible bacteria.

• Community‑acquired pneumonia: improves clinical cure rates by targeting typical and atypical pathogens.
• Acute bacterial sinusitis: reduces symptom duration and bacterial load.
• Complicated skin and skin‑structure infections: provides bactericidal activity against Gram‑negative and Gram‑positive organisms.
• Intra‑abdominal infections: effective against mixed aerobic and anaerobic flora when used intravenously.
• Acute bacterial exacerbation of chronic bronchitis: shortens recovery time and limits disease progression.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA breaks, leading to rapid bacterial cell death and a broad spectrum of antibacterial activity.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: often self‑limiting watery stools.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensations.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: risk of ventricular arrhythmias.
• Clostridioides difficile infection: severe colitis following gut flora disruption.
• Severe allergic reactions: anaphylaxis, angioedema.
• Hepatic failure: rare but potentially life‑threatening liver injury.
• Peripheral neuropathy: persistent sensory deficits.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

• Renal function assessment: adjust therapy in severe impairment.
• QT interval monitoring: avoid in patients with known prolongation or concurrent QT‑prolonging drugs.
• Tendon disorder avoidance: do not use in patients with a history of tendon disease.
• Hepatic impairment caution: monitor liver enzymes during treatment.
• Concomitant medication review: assess for drugs that may increase toxicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increase risk of arrhythmia.
• Antacids containing aluminum or magnesium: reduce oral absorption (not applicable to IV but caution with concurrent oral forms).
• Warfarin: may potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely)

• NSAIDs: heightened risk of CNS stimulation and seizures.
• Corticosteroids: additive risk of tendon rupture.
• Cyclosporine: possible increase in moxifloxacin plasma concentrations.